Source comparison
Best KPV Dosage Colitis 2026: Protocol Comparison
Single Daily Bolus 2000 mcg Once daily (AM) Peak 40–60 μM, trough <2 μM Moderate (45% from baseline) Low (intermittent exposure) Suboptimal. Long trough periods allow inflammatory rebound between doses Split Twice-Daily 1000 mcg × 2 Every 12 hours Sustained 8–
This comparison does not assign a generated winner or score.
- Single Daily Bolus
- 2000 mcg
- Once daily (AM)
- Peak 40–60 μM, trough <2 μM
- Moderate (45% from baseline)
- Low (intermittent exposure)
- Suboptimal. Long trough periods allow inflammatory rebound between doses
- Split Twice-Daily
- 1000 mcg × 2
- Every 12 hours
- Sustained 8–20 μM
- High (63% from baseline)
- Low to moderate
- Optimal for most colitis models. Maintains therapeutic window without saturation
- High-Dose Single
- 3000 mcg
- Peak >100 μM, trough <3 μM
- Moderate (50% from baseline)
- High (receptor saturation)
- Inefficient. Saturates MC1R without additive benefit, accelerates tolerance
- Continuous Infusion
- 1200 mcg (50 mcg/hr × 24h)
- Osmotic pump
- Stable 10–15 μM
- Very high (70% from baseline)
- Moderate (sustained exposure)
- Maximum efficacy but impractical. Requires surgical implantation
- Conservative Split
- 500 mcg × 2
- Sustained 5–12 μM
- Moderate-high (55% from baseline)
- Very low
- Best starting protocol. Lower cost, minimises receptor adaptation, scalable upward
- The twice-daily split protocol at 500–1000 mcg per dose consistently delivers the best balance of efficacy, cost efficiency, and receptor preservation across published colitis studies.